DDInter1570 DDInter1802
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ticagrelor
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ticagrelor
Ranolazine {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Ticagrelor
Ranolazine {u} (Compound) resembles {v} (Compound) Carvedilol
Carvedilol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ranolazine {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ranolazine {u} (Compound) causes {v} (Side Effect) Nephropathy toxic
Nephropathy toxic {u} (Side Effect) is caused by {v} (Compound) Ibuprofen
Ibuprofen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ranolazine {u} (Compound) causes {v} (Side Effect) Serum creatinine increased
Serum creatinine increased {u} (Side Effect) is caused by {v} (Compound) Dolutegravir
Dolutegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Guaifenesin {u} (Compound) resembles {v} (Compound) Penbutolol
Penbutolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Ranolazine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Ticagrelor (Compound)
Ranolazine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Ranolazine (Compound) resembles Carvedilol (Compound) and Carvedilol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Ranolazine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ranolazine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Ranolazine (Compound) causes Nephropathy toxic (Side Effect) and Nephropathy toxic (Side Effect) is caused by Ibuprofen (Compound) and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Ranolazine (Compound) causes Serum creatinine increased (Side Effect) and Serum creatinine increased (Side Effect) is caused by Dolutegravir (Compound) and Dolutegravir may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Ranolazine (Compound) resembles Guaifenesin (Compound) and Guaifenesin (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor